Skip to content

Application of targeted FAP radionuclide labeled cyclic peptide imaging agents in tumor diagnosis, staging, efficacy monitoring, re staging, and prognosis evaluation

Application of targeted FAP radionuclide labeled cyclic peptide imaging agents in tumor diagnosis, staging, efficacy monitoring, re staging, and prognosis evaluation

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076976
Enrollment
Unknown
Registered
2023-10-25
Start date
2023-06-07
Completion date
Unknown
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumors

Interventions

2. Radiology: 18F-FDG PET/CT 3. Pathology.

Sponsors

The First Affiliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients with suspected tumors who cannot be clearly diagnosed as tumors using other imaging methods such as ultrasound, CT, MRI, etc. (2) The patient's general condition is acceptable and can tolerate PET examination. (3) Positive individuals with FAP cyclic peptide PET/CT imaging. (4) After previous treatment, there is no satisfactory alternative treatment plan for refractory or progressive advanced/metastatic solid tumors. (5) Age = 18 years old, life expectancy = 6 months. (6) ECOG PS 0 or 1. (7) Diseases that can be measured according to RECIST. (8) There has been no systemic radioactive therapy in the past.

Exclusion criteria

Exclusion criteria: (1) Clinically significant impairment of bone marrow, liver, and kidney function, such as platelet count<75 × 10^9/L, neutrophil count<1.5 × 10^9, hemoglobin concentration<90 g/L or albumin concentration = 25 g/L, GFR<40 ml/min. (2) Simultaneously using nephrotoxic drugs, there has been radiotherapy for a single evaluable lesion in the past (6 weeks) or uncontrollable complications. (3) Those who have fertility requirements within six months and are unable to withstand radiation risks. (4) Non tumor patients.

Design outcomes

Primary

MeasureTime frame
SUVmax;SUVmean;TBR;Sensitivity, specificity, accuracy;Dosimetry;

Secondary

MeasureTime frame
Metabolic tumor volume;

Countries

China

Contacts

Public ContactWang Xinlu

The First Affiliated Hospital of Guangzhou Medical University

71Lu@163.com+86 132 2661 6001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026